191 related articles for article (PubMed ID: 24599585)
1. Impact of COX2 genotype, ER status and body constitution on risk of early events in different treatment groups of breast cancer patients.
Markkula A; Simonsson M; Rosendahl AH; Gaber A; Ingvar C; Rose C; Jernström H
Int J Cancer; 2014 Oct; 135(8):1898-910. PubMed ID: 24599585
[TBL] [Abstract][Full Text] [Related]
2. IL6 genotype, tumour ER-status, and treatment predicted disease-free survival in a prospective breast cancer cohort.
Markkula A; Simonsson M; Ingvar C; Rose C; Jernström H
BMC Cancer; 2014 Oct; 14():759. PubMed ID: 25305747
[TBL] [Abstract][Full Text] [Related]
3. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy.
Lei J; Rudolph A; Moysich KB; Rafiq S; Behrens S; Goode EL; Pharoah PP; Seibold P; Fasching PA; Andrulis IL; Kristensen VN; Couch FJ; Hamann U; Hooning MJ; Nevanlinna H; Eilber U; Bolla MK; Dennis J; Wang Q; Lindblom A; Mannermaa A; Lambrechts D; García-Closas M; Hall P; Chenevix-Trench G; Shah M; Luben R; Haeberle L; Ekici AB; Beckmann MW; Knight JA; Glendon G; Tchatchou S; Alnæs GI; Borresen-Dale AL; Nord S; Olson JE; Hallberg E; Vachon C; Torres D; Ulmer HU; Rüdiger T; Jager A; van Deurzen CH; Tilanus-Linthorst MM; Muranen TA; Aittomäki K; Blomqvist C; Margolin S; Kosma VM; Hartikainen JM; Kataja V; Hatse S; Wildiers H; Smeets A; Figueroa J; Chanock SJ; Lissowska J; Li J; Humphreys K; Phillips KA; ; Linn S; Cornelissen S; van den Broek SA; Kang D; Choi JY; Park SK; Yoo KY; Hsiung CN; Wu PE; Hou MF; Shen CY; Teo SH; Taib NA; Yip CH; Ho GF; Matsuo K; Ito H; Iwata H; Tajima K; Dunning AM; Benitez J; Czene K; Sucheston LE; Maishman T; Tapper WJ; Eccles D; Easton DF; Schmidt MK; Chang-Claude J
Breast Cancer Res; 2015 Feb; 17(1):18. PubMed ID: 25849327
[TBL] [Abstract][Full Text] [Related]
4. COX2 overexpression is a prognostic marker for Stage III breast cancer.
Kim HS; Moon HG; Han W; Yom CK; Kim WH; Kim JH; Noh DY
Breast Cancer Res Treat; 2012 Feb; 132(1):51-9. PubMed ID: 21533532
[TBL] [Abstract][Full Text] [Related]
5. No association found between CYP2D6 genotype and early breast cancer events in tamoxifen-treated patients.
Markkula A; Hjertberg M; Rose C; Ingvar C; Jernström H
Acta Oncol; 2014 Feb; 53(2):195-200. PubMed ID: 24125101
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-6 -174G-->C polymorphism is associated with improved outcome in high-risk breast cancer.
DeMichele A; Martin AM; Mick R; Gor P; Wray L; Klein-Cabral M; Athanasiadis G; Colligan T; Stadtmauer E; Weber B
Cancer Res; 2003 Nov; 63(22):8051-6. PubMed ID: 14633738
[TBL] [Abstract][Full Text] [Related]
7. Coffee prevents early events in tamoxifen-treated breast cancer patients and modulates hormone receptor status.
Simonsson M; Söderlind V; Henningson M; Hjertberg M; Rose C; Ingvar C; Jernström H
Cancer Causes Control; 2013 May; 24(5):929-40. PubMed ID: 23412805
[TBL] [Abstract][Full Text] [Related]
8. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
9. High estrogen receptor expression in early breast cancer: chemotherapy needed to improve RFS?
Regierer AC; Wolters R; Kurzeder C; Wöckel A; Novopashenny I; Possinger K; Wischnewsky MB; Kreienberg R
Breast Cancer Res Treat; 2011 Jul; 128(1):273-81. PubMed ID: 21210206
[TBL] [Abstract][Full Text] [Related]
10. Effects of tumor-specific CAP1 expression and body constitution on clinical outcomes in patients with early breast cancer.
Bergqvist M; Elebro K; Sandsveden M; Borgquist S; Rosendahl AH
Breast Cancer Res; 2020 Jun; 22(1):67. PubMed ID: 32560703
[TBL] [Abstract][Full Text] [Related]
11. The prognostic effect of estrogen receptor status differs for younger versus older breast cancer patients.
Sopik V; Sun P; Narod SA
Breast Cancer Res Treat; 2017 Sep; 165(2):391-402. PubMed ID: 28601929
[TBL] [Abstract][Full Text] [Related]
12. CYP1A2--a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients.
Simonsson M; Veerla S; Markkula A; Rose C; Ingvar C; Jernström H
BMC Cancer; 2016 Mar; 16():256. PubMed ID: 27029552
[TBL] [Abstract][Full Text] [Related]
13. Polymorphism at 19q13.41 Predicts Breast Cancer Survival Specifically after Endocrine Therapy.
Khan S; Fagerholm R; Rafiq S; Tapper W; Aittomäki K; Liu J; Blomqvist C; Eccles D; Nevanlinna H
Clin Cancer Res; 2015 Sep; 21(18):4086-4096. PubMed ID: 25964295
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor CAG repeat length and estrogen receptor status in postmenopausal breast cancer prognosis.
Cogliati P; Ciniselli CM; Agresti R; Paolini B; Bonini C; Radice P; Krogh V; Verderio P; Venturelli E
Int J Biol Markers; 2015 Nov; 30(4):e418-24. PubMed ID: 26541420
[TBL] [Abstract][Full Text] [Related]
15. Coexpression of NOS2 and COX2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer.
Basudhar D; Glynn SA; Greer M; Somasundaram V; No JH; Scheiblin DA; Garrido P; Heinz WF; Ryan AE; Weiss JM; Cheng RYS; Ridnour LA; Lockett SJ; McVicar DW; Ambs S; Wink DA
Proc Natl Acad Sci U S A; 2017 Dec; 114(49):13030-13035. PubMed ID: 29087320
[TBL] [Abstract][Full Text] [Related]
16. Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy.
Laible M; Hartmann K; Gürtler C; Anzeneder T; Wirtz R; Weber S; Keller T; Sahin U; Rees M; Ramaswamy A
BMC Cancer; 2019 Jul; 19(1):694. PubMed ID: 31307414
[TBL] [Abstract][Full Text] [Related]
17. Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer.
Loo CE; Rigter LS; Pengel KE; Wesseling J; Rodenhuis S; Peeters MJ; Sikorska K; Gilhuijs KG
Breast Cancer Res; 2016 Aug; 18(1):82. PubMed ID: 27495815
[TBL] [Abstract][Full Text] [Related]
18. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
19. Cyclooxygenase-2 (COX2) and p53 protein expression are interdependent in breast cancer but not associated with clinico-pathological surrogate subtypes, tumor aggressiveness and patient survival.
Serra KP; Peres RM; Sarian LO; Vassallo J; Pinto GA; Silva GR; Soares FA; da Cunha IW; Espinola J; Bento AM; Del Corso LM; Derchain S
Acta Histochem; 2016 Mar; 118(2):176-82. PubMed ID: 26791786
[TBL] [Abstract][Full Text] [Related]
20. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
Regan MM; Pagani O; Francis PA; Fleming GF; Walley BA; Kammler R; Dell'Orto P; Russo L; Szőke J; Doimi F; Villani L; Pizzolitto S; Öhlschlegel C; Sessa F; Peg Cámara V; Rodríguez Peralto JL; MacGrogan G; Colleoni M; Goldhirsch A; Price KN; Coates AS; Gelber RD; Viale G;
Breast Cancer Res Treat; 2015 Nov; 154(2):275-86. PubMed ID: 26493064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
